Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials

Medical Oncology

Volumn 32, Issue 2, 2015, Pages

  Su, Wenmei ^a   Lai, Zhennan ^a   Wu, Fenping ^b   Lin, Yanming ^a   Mo, Yanli ^a   Yang, Zhixiong ^a   Wu, Jiayuan ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b Seventh People's Hospital   (China)

Author keywords

Ifosfamide; Neoadjuvant chemotherapy; Osteosarcoma; Randomized controlled trials

Indexed keywords

IFOSFAMIDE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; COCHRANE LIBRARY; EMBASE; EVENT FREE SURVIVAL; HUMAN; INFORMATION RETRIEVAL; INTERNET; LIMB SALVAGE; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SYSTEMATIC REVIEW; ADJUVANT THERAPY; BONE NEOPLASMS; MORTALITY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; HUMANS; IFOSFAMIDE; NEOADJUVANT THERAPY; OSTEOSARCOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84920771292     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0481-y     Document Type: Article

References (28)

1. Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol. 2010;11:670–8.
2. van Dalen EC, van As JW, de Camargo B. Methotrexate for high-grade osteosarcoma in children and young adults. Cochrane Database Syst Rev. 2011;5:CD006325.
3. Smelangd S, et al. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma. Acta Orthop. 2011;82:211–6.
4. Bacci G, et al. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group Pilot Study. J Chemother. 2002;14:198–206.
5. Le Deley MC, et al. SFOP OS94: a randomized trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007;43:752–61.
6. Bacci G, et al. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur J Surg Oncol. 2001;27:98–104.
7. Ferrari S, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an italian sarcoma group trial ISG/OS-1. J Clin Oncol. 2012;30:2112–8.
8. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic review and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.
9. Maxwell L, et al. Method guidelines for Cochrane Musculoskeletal Group systematic reviews. J Rheumatol. 2006;33:2304–11.
10. Wells GA, et al. The Newcastle-Ottawa Scala (NOS) for assessing the quality of nonrandomized studies in meta-analyses, Ottawa Health Research Institute Web site. 2012.
11. Deeks J, Higgins JPT. Analysis data and undertaking meta-analyses. In: Cochrane handbook for systematic reviews of interventions 5.0.0. http://www.cochrane-handbook.org. Accessed 15 July 2011.
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
13. Mantel N, Haenszel E. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.
14. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
15. Meyer PA, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004–11.
16. Hong S, et al. Comparison of long-term outcome between doublet and triblet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity. Oncology. 2011;80:107–17.
17. Whelan JS, et al. Survival from high-grade localized extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomized controlled trials. Ann Oncol. 2012;23:1607–16.
18. Marti C, et al. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep. 1985;69:115–7.
19. Pratt CB, et al. Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep. 1987;71:131–5.
20. Bacci G, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Instituto Ortopedico Rizzoli according to the Instituto Ortopedico/Osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016–27.
21. Lin F, et al. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol. 2011;7:270–5.
22. Kudawara I, et al. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan. J Chemother. 2013;25:41–8.
23. Bacci G, et al. Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years. Tumori. 2004;90:478–84.
24. Bacci G, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at single institution. Cancer. 2006;106:1154–61.
25. Durnali A, et al. Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients. Med Oncol. 2013;30:624.
26. Smeland S, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer. 2003;39:488–94.
27. Goorin AM, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21:1574–80.
28. Yin K, et al. Meta-analysis of limb salvage versus amputation for treating high-grade and localized osteosarcoma in patients with pathological fracture. Exp Ther Med. 2012;4:889–94.